Formulation, characterization, and cytotoxicity evaluation of lactoferrin functionalized lipid nanoparticles for riluzole delivery to the brain

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a very poor prognosis. Its treatment is hindered by a lack of new therapeutic alternatives and the existence of the blood–brain barrier (BBB), which restricts the access of drugs commonly used in ALS, such as riluzole, to the br...

ver descrição completa

Detalhes bibliográficos
Autor principal: Teixeira, Maria Inês (author)
Outros Autores: Lopes, Carla Martins (author), Gonçalves, Hugo (author), Catita, José António Morais (author), Silva, Ana Margarida (author), Rodrigues, Francisca (author), Amaral, Maria Helena (author), Costa, Paulo C. (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
Blood–brain barrier (BBB)
Brain delivery
Neurodegenerative diseases
Amyotrophic lateral sclerosis (ALS)
Lipid nanoparticle
Nanostructured lipid carriers (NLC)
Riluzole
Lactoferrin
Lactoferrin receptors
Drug targeting
Texto completo:http://hdl.handle.net/10284/10656
País:Portugal
Oai:oai:bdigital.ufp.pt:10284/10656

Texto Completo

http://hdl.handle.net/10284/10656

Registos relacionados